June 26, 2007
New VP for RXi
By Cory Hopkins
Worcester-based RXi Pharmaceuticals Corp., a majority-owned subsidiary of CytRx Corp. of Los Angeles, announced the hiring of Dmitry Samarsky as vice president of technology development today.
Samarsky previously served as the director of technology development at Dharmacon Inc., a Lafayette, Colo.-based division of Thermo Fisher Scientific, where he helped promote the company's RNAi technology program and establish an RNAi applications laboratory.
"Dr. Samarsky brings RXi unmatched experience in the development and licensing of RNAi technologies," said Tod Woolf, RXi's president and CEO. "Dr. Samarsky will lead efforts to expand our RNAi-based therapeutics platform and promote our leading programs to major biotechnology and pharmaceutical companies."
RXi is a biopharmaceutical company that focuses on developing RNAi-based therapeutics for the treatment of human disease. University of Massachusetts professor Craig Mello, recently awarded the Nobel Prize for his part in the discovery of RNAi, is one of the founders of RXi.
Samarsky previously served as the director of technology development at Dharmacon Inc., a Lafayette, Colo.-based division of Thermo Fisher Scientific, where he helped promote the company's RNAi technology program and establish an RNAi applications laboratory.
"Dr. Samarsky brings RXi unmatched experience in the development and licensing of RNAi technologies," said Tod Woolf, RXi's president and CEO. "Dr. Samarsky will lead efforts to expand our RNAi-based therapeutics platform and promote our leading programs to major biotechnology and pharmaceutical companies."
RXi is a biopharmaceutical company that focuses on developing RNAi-based therapeutics for the treatment of human disease. University of Massachusetts professor Craig Mello, recently awarded the Nobel Prize for his part in the discovery of RNAi, is one of the founders of RXi.
WBJ Web Partners
Most Recent
Most Recent
0 Comments